Skip to main content

Table 1 CD47-related clinical trials registered in US national clinical trials registry (NCT) system www.clinicaltrials.gov

From: Targeting CD47 for cancer immunotherapy

Agent

CD47 Isotype

Organization

Mechanism of action

NCT Number

Status

Conditions

Phase

Enrollment

Start dates

AK117

IgG4

Akesobio

A new generation of humanized anti-human CD47 IgG4 mAb,

NCT04349969

Not yet recruiting

Neoplasms Malignant

Phase 1

159

25-Apr-20

NCT04728334

Recruiting

Neoplasms Malignant

Phase 1

162

27-Jan-21

NCT04900350

Recruiting

MDS

Phase 1/2

190

18-Jun-21

NCT04980885

Recruiting

AML

Phase 1/2

160

Jul-21

AO-176

IgG2

Arch Oncology

Fully humanized anti-human CD47 monoclonal antibody

NCT03834948

Recruiting

Solid Tumor

Phase 1/2

183

4-Feb-19

NCT04445701

Recruiting

MM

Phase 1/2

102

30-Nov-20

CC-90002

IgG4

Celgene

First generation anti-human CD47 antibody

NCT02367196

Completed

Hematological Malignancies

Phase 1

60

12-Mar-15

CPO107 JMT601 (CPO107)

IgG1 (CD20)

Conjupro Biotherapeutics, Inc

Bi-specific SIRP α and anti-CD20 fusion protein. Through interference of CD47/SIRP α interaction to enhance antibody-dependent phagocytosis (ADCP)

NCT04853329

Not yet recruiting

NHL

Phase 1/2

75

15-Aug-21

DSP107

IgG4

KAHR Medical

Bi-functional CD47 and 41BB fusion protein

NCT04440735

Recruiting

Advanced Solid Tumor

Non-Small Cell Lung Cancer

Phase 1

Phase 2

100

7-Oct-20

NCT04937166

Recruiting

AML/MDS

CML

Phase 1

Phase 2

36

Sep-21

Evorpacept (ALX148)

IgG1

ALX Oncology

Fusion protein of SIRPα D1 domain and an inactive human IgG1 Fc

NCT03013218

Active, not recruiting

Solid Tumor

NHL

Phase 1

174

3-Feb-17

NCT04417517

Recruiting

MDS

Phase 1

173

2-Oct-20

NCT04675294

Recruiting

Head and Neck Squamous Cell Carcinoma

Phase 2

111

April 2, 2021

NCT04675333

Recruiting

Head and Neck Squamous Cell Carcinoma

Phase 2

112

10-May-21

NCT04755244

Recruiting

AML

Phase 1/2

97

5-May-21

NCT05002127

Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Phase 2/3

450

Aug-21

Hu5F9-G4 Magrolimab(5F9)

IgG4

Gilead Sciences/Forty Seven

Anti-human CD47 mAb

NCT02216409

Completed

Solid Tumor

Phase 1

88

Aug-14

NCT02678338

Completed

AML/MDS

Phase 1

20

Nov-15

NCT03248479

Recruiting

Hematological Malignancies

Phase 1

287

8-Sep-17

NCT03527147

Completed

NHL

DLBCL

NHL

Diffuse Large B Cell Lymphoma

Phase 1

30

19-Jun-18

NCT04599634

Not yet recruiting

Follicular Lymphoma

Marginal Zone Lymphoma

Mantle Cell Lymphoma

Chronic Lymphocytic Lymphoma

B-Cell Lymphoma

Phase 1

76

1-Sep-21

HX009

IgG4

Hanxbio

PD-1/CD47 bi-specific mAb

NCT04097769

Active, not recruiting

Advanced Solid Tumor

Phase 1

20

18-Mar-21

NCT04886271

Recruiting

Solid Tumor

Phase 2

210

10-May-21

IBI188

IgG4

Innovent Bio

Recombinant human anti-CD47 mAb

NCT03717103

Active, not recruiting

Advanced Malignancies

Phase 1

49

10-Jan-19

NCT03763149

Active, not recruiting

Advanced Malignancies

Phase 1

42

11-Jan-19

NCT04485052

Recruiting

AML

Phase 1

Phase 2

126

Apr-21

NCT04485065

Recruiting

MDS

Phase 1

12

30-Sep-20

NCT04861948

Recruiting

Solid Tumors

Lung Adenocarcinoma

Osteosarcoma

Phase 1

120

25-May-21

IBI322

IgG4

Innovent Bio

Bi-specific antibody that can target CD47 and PD-L1

NCT04328831

Recruiting

Advanced Malignancies

Phase 1

218

31-Jul-20

NCT04338659

Recruiting

Advanced Malignancies

Phase 1

45

Apr-21

NCT04795128

Recruiting

Hematological Malignancies

Phase 1

230

7-May-21

NCT04912466

Recruiting

Solid Tumor

Phase 1

36

20-Jun-21

IMC-002

IgG4

ImmuneOncia Therapeutics

3D Medicines

Anti-human CD47 monoclonal antibody

NCT04306224

Recruiting

Solid Tumor

NHL

Phase 1

24

5-Jun-20

IMM0306

IgG1

ImmneOnco

Bi-specific antibody targeting CD47 and CD20 at the same time

NCT04746131

Not yet recruiting

NHL

Phase 1

90

15-Aug-21

OSE-172

IgG4

OSE Immunotherapeutics

Humanized IgG4 mAb against SIRPα

NCT04806035

Recruiting

CLL

SLL

Richter's Transformation

Indolent Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Aggressive Lymphoma

DLBCL

Mediastinal Large B-cell Lymphoma

MCL

Phase 1

60

23-Apr-21

PF-07257876

IgG4

Pfizer

Bi-specific antibody against CD47 and PD-L1,

NCT04881045

Not yet recruiting

Non-Small Cell Lung Cancer

Head and Neck Squamous Cell Carcinoma

Ovarian Cancer

Phase 1

90

27-Aug-21

SHR-1603

IgG4

Jiangsu HengRui Medicine

Humanized IgG4 mAb targeting CD47

NCT03722186

Suspended

Physiological Effects of Drugs

Neoplasms by Histologic Type

NHL

Phase 1

128

13-Nov-18

SHR2150

IgG4 (TLR7)

HengRui Pharma

Selective TLR7 receptor agonist

NCT04588324

Recruiting

Solid Tumor

Phase 1/2

50

10-Oct-20

SRF231

IgG4

Surface Oncology

Anti-human CD47 mAb

NCT03512340

Completed

Advanced Solid Cancers

Hematological Malignancies

Phase 1

148

13-Mar-18

STI-6643

IgG4

Sorrento Therapeutics, Inc

Fully humanized anti-CD47 mAb

NCT04900519

Not yet recruiting

Solid Tumor

Phase 1

24

Aug-21

TG-1801

IgG4

Novimmune SA

TG Therapeutics

Bi-specific mAb targeting both CD19 and CD47

NCT03804996

Recruiting

NHL

Phase 1

16

5-Mar-19

TJ011133

IgG4

I-MAB Biopharma

Highly differentiated CD47 monoclonal antibody

NCT04895410

Not yet recruiting

MM

Phase 1

163

13-Jul-21

NCT04912063

Recruiting

AML/MDS

Phase 1

120

15-Jun-21

TTI-621

IgG1

Trillium Therapeutics Inc

SIRPα-IgG1 Fc, checkpoint inhibitor CD47 blocker,

NCT02663518

Recruiting

Hematological Malignancies

Solid Tumor

Phase 1

260

Jan-16

NCT04996004

Recruiting

Leiomyosarcoma

Phase 1/2

80

25-Jun-21

ZL-1201

IgG4

Zai Lab

Anti-human CD47 mAb

NCT04257617

Recruiting

Advanced Malignancies

Phase 1

66

11-May-20